SEC Info  
    Home      Search      My Interests      Help      Sign In      Please Sign In

diaDexus, Inc. – ‘8-K’ for 10/21/02

On:  Tuesday, 10/22/02, at 2:13pm ET   ·   For:  10/21/02   ·   Accession #:  1169232-2-2206   ·   File #:  0-26483

Previous ‘8-K’:  ‘8-K’ on 10/4/02 for 10/3/02   ·   Next:  ‘8-K’ on 11/7/02 for 11/5/02   ·   Latest:  ‘8-K’ on 4/29/16 for 4/28/16

  in    Show  and    Hints

  As Of                Filer                Filing    For·On·As Docs:Size              Issuer               Agent

10/22/02  diaDexus, Inc.                    8-K:5,7    10/21/02    2:9K                                     Edgar Ease Svc Bureau/FA

Current Report   —   Form 8-K
Filing Table of Contents

Document/Exhibit                   Description                      Pages   Size 

 1: 8-K         Current Report                                         4      9K 
 2: EX-99.1     Press Release Issued October 21, 2002                  2     10K 


8-K   —   Current Report
Document Table of Contents

Page (sequential) | (alphabetic) Top
 
11st Page   -   Filing Submission
2Item 5. Other Events
"Item 7. Financial Statements, Pro Forma Financial Information and Exhibits
8-K1st Page of 4TOCTopPreviousNextBottomJust 1st
 

SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 ------------------------- FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 21, 2002 VAXGEN, INC. (Exact name of Registrant as Specified in its Charter) DELAWARE 0-26483 94-3236309 (State or other jurisdiction (Commission (I.R.S. Employer incorporation of Identification Number) File Number) or organization) 1000 MARINA BLVD., SUITE 200 BRISBANE, CALIFORNIA 94005 (Address of Principal Administrative Offices) Registrants Telephone Number, Including Area Code: (650) 624-1000
8-K2nd Page of 4TOC1stPreviousNextBottomJust 2nd
Item 5. Other Events. On October 21, 2002, VaxGen, Inc. (the "Company") announced that the independent board that oversees the Company's clinical trials completed the final safety and conduct review of the Company's Phase III trial in Thailand and once again concluded that the study was being conducted appropriately and that the Company's AIDS vaccine candidate appears safe. The independent board also conducted an interim analysis of efficacy using data from the trial in Thailand and recommended that the study continue to its planned conclusion in the second half of 2003. The press release is filed herewith as Exhibit 99.1 and incorporated herein by reference. Item 7. Financial Statements, Pro Forma Financial Information and Exhibits. (c) Exhibits. EXHIBIT DESCRIPTION 99.1 Press Release issued October 21, 2002.
8-K3rd Page of 4TOC1stPreviousNextBottomJust 3rd
SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. VaxGen, Inc. (Registrant) Dated: October 22, 2002 By: /s/ Carter A. Lee --------------------------- Carter A. Lee Senior Vice President Finance & Administration
8-KLast Page of 4TOC1stPreviousNextBottomJust 4th
EXHIBIT INDEX EXHIBIT No. DESCRIPTION ----------- ----------- 99.1 Press Release issued October 21, 2002.

Dates Referenced Herein

Referenced-On Page
This ‘8-K’ Filing    Date First  Last      Other Filings
Filed on:10/22/023None on these Dates
For Period End:10/21/0214
 List all Filings 
Top
Filing Submission 0001169232-02-002206   –   Alternative Formats (Word / Rich Text, HTML, Plain Text, et al.)

Copyright © 2020 Fran Finnegan & Company.  All Rights Reserved.
AboutPrivacyRedactionsHelp — Sat., Jan. 18, 11:28:08.0pm ET